The Translational Imaging in Drug Safety Assessment project (TRISTAN)
Biomarkers based on imaging techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) are not currently widely used in drug discovery, despite their potential to offer non-invasive insights regarding safety and toxicity early in the drug development process.
We are proud to be a partner of the TRISTAN consortium collaboration. The goal of the project is to validate or qualify the use of imaging biomarkers to assess toxicity of potential treatments, thereby advancing drug development by improving the translatability of preclinical data to clinical development. Part of the TRISTAN project is focused on using imaging biomarkers derived from dynamic contrast enhanced MRI (DCE-MRI) with gadoxetate to understand harmful changes in liver transport flux.
Antaros Medical has been contributing to the preclinical validation of gadoxetate imaging and developing an imaging assay of liver function. You can also read more about Antaros Medical’s work with gadoxetate in clinical drug development here. For more information about the assay, please contact info@antarosmedical.com.
The TRISTAN consortia is a public-private partnership bringing together 21 organisations including academics, research organisations, small and medium-size enterprises (SMEs), imaging and pharmaceutical companies.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Link to IMI website: https://www.imi.europa.eu/
Link to TRISTAN website: https://www.imi-tristan.eu/
Link to IMI Project Factsheet: https://www.imi.europa.eu/projects-results/project-factsheets/tristan
TRISTAN Consortium partners:
- Coordinator: European Organisation for Research and Treatment of Cancer (EORTC)
- Lead: Bayer
- Co-lead: GlaxoSmithKline (GSK)
- Partners: Abbvie, Antaros Medical, Bioxydyn, Bruker, Chalmers University of Technology, GE Healthcare, Lund University, Merck Sharp & Dohme (MSD), Radboud University Nijmegen, Novo Nordisk, Pfizer, Sanofi, , Truly Labs, Université de Bourgogne Dijon, University Medical Center Groningen (UMCG), University of Leeds, University of Manchester, University of Sheffield/Sheffield Teaching Hospitals NHS Trust
Publications
Kenna JG, Waterton JC, Baudy A, Galetin A, Hines CDG, Hockings P, Patel M, Scotcher D, Sourbron S, Ziemian S, Schuetz G. 2018. Noninvasive preclinical and clinical imaging of liver transporter function relevant to drug-induced liver injury. In Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology.
Waterton JC, Hines CDG, Hockings PD, Laitinen I, Ziemian S, Campbell S, Gottschalk M, Green C, Haase M, Hassemer K, Juretschke HP, Koehler S, Lloyd W, Luo Y, Mahmutovic Persson I, O’Connor JPB, Olsson LE, Pindoria K, Schneider JE, Sourbron S, Steinmann D, Strobel K, Tadimalla S, Teh I, Veltien A, Zhang X, Schütz G. 2019. Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systems. Magn Reson Imaging.
Melillo N, Scotcher D, Kenna JG, Green C, Hines CDG, Laitinen I, Hockings PD, Ogungbenro K, Gunwhy ER, Sourbron S, Waterton JC, Schuetz G, Galetin A. 2023. Use of in vivo imaging and physiologically-based kinetic modelling to predict hepatic transporter mediated drug-drug interactions in rats. Pharmaceutics.
Gunwhy ER, Hines CDG, Green C, Laitinen I, Tadimalla S, Hockings PD, Schütz G, Kenna JG, Sourbron S, Waterton JC. 2024. Assessment of hepatic transporter function in rats using dynamic gadoxetate-enhanced MRI: a reproducibility study. MAGMA.